Delving into the Latest Updates on M.W. Encap Ltd. with Synapse

Overview

Basic Info

Introduction

M.W. Encap Ltd., a subsidiary of Lonza Group AG, is a UK-based pharmaceutical company that specializes in the production of liquid-filled hard capsules. Established in 1994, the company has since become a global leader in this field, possessing the necessary expertise, equipment, and facilities to develop and manufacture these products under GMP conditions for both clinical and commercial use. In March 2013, the company was acquired by Capsugel, Inc.

Tags

Otorhinolaryngologic Diseases

Nervous System Diseases

Hemic and Lymphatic Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Nervous System Diseases	1
Hemic and Lymphatic Diseases	1
Infectious Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Tubulin	1

主要目的：向在研究 KX-ORAX-CN-007中完成了Oraxol治疗，获得完全缓解（CR），部分缓解（PR），或病情稳定（SD），且希望继续治疗的患者和其他转移性乳腺癌患者提供进一步治疗，并进一步评估Oraxol在乳腺癌患者中的安全性。次要目的：进一步评估Oraxol 在乳腺癌患者中的有效性

[Translation]

Primary objective: To provide further treatment to patients who have completed Oraxol treatment in study KX-ORAX-CN-007 and achieved complete remission (CR), partial remission (PR), or stable disease (SD) and wish to continue treatment, and to other patients with metastatic breast cancer, and to further evaluate the safety of Oraxol in patients with breast cancer. Secondary objective: To further evaluate the effectiveness of Oraxol in patients with breast cancer

Start Date29 Aug 2019

Sponsor / Collaborator

Athenex, Inc.

[+3]

CTR20190531

/ Active, not recruitingPhase 1

一项确定Oraxol在乳腺癌患者中药代动力学的临床研究

[Translation] A clinical study to determine the pharmacokinetics of Oraxol in breast cancer patients

主要目的：考察乳腺癌患者口服紫杉醇（Oraxol）的PK（AUC）次要目的：确定Oraxol在乳腺癌患者中的安全性和有效性（疗效率，无进展生存[PFS]），总生存[OS]）

[Translation]

Primary objective: To investigate the PK (AUC) of oral paclitaxel (Oraxol) in patients with breast cancer Secondary objective: To determine the safety and efficacy (efficacy rate, progression-free survival [PFS], overall survival [OS]) of Oraxol in patients with breast cancer

Start Date13 May 2019

Sponsor / Collaborator

Athenex, Inc.

[+3]

100 Clinical Results associated with M.W. Encap Ltd.

Login to view more data

0 Patents (Medical) associated with M.W. Encap Ltd.

Login to view more data

3

Literatures (Medical) associated with M.W. Encap Ltd.

Pharmaceutical Technology

Capsule-in-capsule technology

Author: Bowtle, W. J.

In a single dosage-unit, capsule-in-capsule formats provide various release phases for a single or multidrug substance.The format also may deliver combinations of compounds that otherwise would be incompatible.The author outlines how to choose carriers and capsule shells according to dosage requirements and intended use.Example in vitro data demonstrate the flexibility of the capsule-in-capsule system.Finally, the author examines the approach's suitability for manufacturing and commercialization.

Pharmaceutical Technology

Challenges in the secondary manufacture of encapsulated high-potency drugs

Author: Dixon, Andrew ; Carey, Joe

A review.High-potency drugs are projected to account for a larger amount of the pharmaceutical industry's com. output and developmental pipelines in the future.Liquid and semisolid encapsulation using two-piece hard capsules is an ideal drug delivery approach for highly potent compounds and poorly water-soluble drugs.The authors detail the factors to reduce risk when designing and operating a facility for secondary manufacturing of highly potent drugs.

Drugs and the Pharmaceutical Sciences

Materials, process, and manufacturing considerations for lipid-based hard-capsule formats

Author: Bowtle, William J.

A review describes the material-selection and process issues for oral lipid-based formulations with an emphasis on their use in hard-capsule format.To provide a basis for the successful manufacture of a novel lipid-based oral dosage form, options in formulation excipients and capsule shell selection are discussed along with the main processing routes employed.

100 Deals associated with M.W. Encap Ltd.

Login to view more data

100 Translational Medicine associated with M.W. Encap Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Other

Login to view more data